SCHEMBL3350408

SCHEMBL3350408

Cc1c(C(N)=O)cc(-c2nccs2)cc1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 1/20 0.46
CHEK2 O96017 1/20 0.46
LRRK2 Q5S007 1/20 0.42
PDPK1 O15530 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
MYC P01106 1/20 0.39
HDAC2 Q92769 2/20 0.39
PIK3CB P42338 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
ADRB2 P07550 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2729191 0.84 CHEK2 (0.43) SMPD3CHEK2LRRK2PTGDR2MYC
SCHEMBL3347230 0.81 CHEK2 (0.41) SMPD3CHEK2LRRK2PDPK1LOXL2
SCHEMBL2729192 0.79 CHEK2 (0.40) SMPD3CHEK2LRRK2PTGDR2ALDH1A1
SCHEMBL2729187 0.78 CHEK2 (0.37) SMPD3CHEK2LRRK2LOXL2MYC
SCHEMBL5755322 0.77 PDPK1 (0.45) CHEK2LRRK2PDPK1PTGDR2MYC
SCHEMBL1932926 0.76 CHEK2 (0.38) SMPD3CHEK2LRRK2PTGDR2MYC
SCHEMBL2726309 0.75 CYP3A4 (0.42) CHEK2LRRK2PDPK1LOXL2ALDH1A1
SCHEMBL3350405 0.75 CHEK2 (0.47) SMPD3CHEK2LRRK2PDPK1LOXL2
SCHEMBL2733045 0.74 TYK2 (0.43) CHEK2PDPK1LOXL2PTGDR2ALDH1A1
SCHEMBL27983939 0.74 CHEK2 (0.39) CHEK2PTGDR2ALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP SMPD3 163/4885CHEK2 3158/4885LRRK2 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.